Collectively, our findings suggest that Rh2 treatment of HepG2 cells could inhibit lipid synthesis and inflammatory responses, thus protecting hepatocytes and potentially preventing NAFLD progression by modulating the interaction between HepG2 cells and THP-1 monocytes. This evidence concerns the gene RHAG and metabolic dysfunction-associated steatotic liver disease.